Chikungunya fever (CHIK) is a febrile illness characterized by acute fever with headache and severe debilitating muscle and joint pain [1, 2] . India had been under the grip of chikungunya since 2005 [3] . Historically, the virus has shown a pattern of affecting immune-naive populations once every 30 years. The first outbreak of the virus occurred in 1963 in Calcutta (now Kolkata) [4] , followed by epidemics in other parts of the country [5, 6] . The last outbreak was recorded in Maharashtra in 1973 [7] . After a gap of more than 30 years, chikungunya reemerged in several Indian states in 2005 and, by 2010, had spread to more than 18 states/union territories within the country. Even though chikungunya is classified as an old World alphavirus not associated with encephalitis, unlike the new World alphaviruses, data of central nervous system involvement appear to support a neuroinfectious association of chikungunya virus (CHIKV) [8] , with a case fatality rate of 1 in 1000 neonates and elderly individuals [9] .
This study was initiated in 2010 during a chikungunya outbreak in India. Two study sites-Delhi and Mumbai-with a comparative total population but different physical geography were chosen. Mumbai is a coastal city and has a long monsoon period, whereas Delhi is land locked, dry, and has a relatively short wet season. Importantly, Mumbai has reported CHIK cases since the 1970s [6] , whereas Delhi reported its first case of CHIK in 2006 [10] . Lastly, the circulating virus strains within these 2 regions were also historically different [11, 12] .
Presented here are the clinical and diagnostic details of 572 patients recruited between 2010 and 2013, CHIKV viral load at the time of admission, and neutralizing potency of these patient samples. After initial recruitment, patients came for follow-up after 12 weeks, and their post-arthralgic features were evaluated using the visual analogue score (VAS). Correlations of viral load, binding, and neutralizing antibodies with the clinical parameters, both at the acute and post-acute phases, provide new insights into disease progression. Also, we compared the infection trend in 2 metropolitan cities in the country.
PATIENTS AND METHODS
Delhi (28.6139°N, 77.2090°E) is located in the northern part of India and Mumbai (19.0760°N, 72.8777°E) is located in the western part of India. The medical system and accessibility to medical care at both sites are of the same standards as defined by the Government of India. VMMC and Safdarjung Hospital (Safdarjung), New Delhi, is a teaching institution and a multispecialty hospital with 1600 beds. BYL Nair Ch. Hospital and T.N. Medical College (Nair), Mumbai, is a teaching institution and a referral hospital for infectious diseases in Mumbai.
Study Participants and Study Design
Recruited patients were part of a study funded by the Department of Biotechnology, Government of India. At the time of clinical evaluation, there was overlap of dengue-like features. Consequently, suspected dengue patients were included in the study for screening purposes (Figure 1 ). The inclusion criteria followed for recruitment included the following: clinical presentation consistent with chikungunya and dengue virus infection (eg, abrupt onset of fever and/or polyarthralgia), onset of symptoms within 10 days preceding the referral, laboratory confirmation of CHIKV infection by positive CHIKV real-time polymerase chain reaction (RT-PCR) results, and/or positive immunoglobulin (Ig)M serologic test results. All samples positive for dengue virus (DENV) by IgM and NS1 enzyme-linked immunosorbent assay (ELISA) were excluded from further analysis.
Clinical Assessment
Patients were assessed in the various wards and out patient department (OPDs) of both hospitals from 2010 through 2013 and recruited upon their written informed consent. All details of their medical history and nature of disease symptoms were selected. Wherever possible, a follow-up was done around 12 weeks post-acute episode, and VAS was assigned by a rheumatologist based on their clinical disease activity index and further rated on a scale of 1-10 on the basis of questions posed to the patients regarding the intensity of their pain.
Serology and Molecular Diagnosis
Post blood sample collection and sera isolation, the sera were subjected to ELISA to test for the presence of CHIKV using CHIKV IgM capture ELISA kits supplied by the National Institute of Virology, Pune, per the manufacturer's instructions. Presence of CHIKV viral RNA was detected using the High Pure Viral Nucleic Acid kit (Roche, Germany) and further processed using Titanium One-Step RT-PCR Kit (Clontech) and primers previously described [13] .
The samples included in the study were selected based on a positive result either by chikungunya IgM ELISA and/or RT-PCR positivity.
Semiquantitative Detection of Chikungunya IgG Antibodies in Patient Sera Samples Using Indirect ELISA
To detect endpoint titers of chikungunya-specific IgG antibodies, indirect ELISA using purified CHIKV as a coating antigen was performed. Purified CHIKV was coated in microtiter plates and left undisturbed overnight at 4°C. Post-blocking, a 2-fold serially diluted patient sample starting at 1:100 was incubated at room temperature for 2 hours. After washing, the plates were developed using anti-human IgG biotin followed by Avidin horseradish peroxidase and 3,3' ,5,5'-tetramethylbenzidine as substrate. Previously characterized samples that were confirmed to have neutralizing antibody to CHIKV were pooled and used as a positive control to obtain a linear curve for absorbance and dilution. Midpoint dilution was calculated for each curve and plotted.
CHIKV Viral Load Determination
Estimation of viral copy number in the patient sera samples was done using the QuantiTect reverse transcription kit (Qiagen, Germany), per the manufacturer's instructions. Using a laboratory-generated reference strain in serial dilution of 100 ng to 1 pg, the exact copy number of CHIKV from viral RNA isolated from patient sera was calculated.
Plaque Reduction Neutralization Test
The neutralization capacity of sera samples from confirmed chikungunya patients was analyzed using a plaque reduction neutralization test (PRNT). Neutralization assay was performed on Vero cells using standard protocol [14] . The results were calculated as PRNT-50. All samples with PRNT-50 at 1:50 or below were scored as nonneutralizing.
Statistical Analyses
Clinical features associated with chikungunya were analyzed, and several nonparametric tests were used to determine statistical significance. Spearman rank test was used to determine the correlation between viral load and days to onset of fever and between absorbance of IgG (at optical density [OD 450 ]) and neutralization status of the patient samples. The Mann-Whitney U test was used to calculate differences in neutralization status of patient samples from the 2 study sites.
RESULTS

Diagnosis of Chikungunya Patient Samples
A total of 810 patients who fulfilled the inclusion criteria were included in the study. During the study period, 400 peripheral blood samples were collected from Safdarjung Hospital, New Delhi, and 410 samples were collected from BYL Nair Hospital, Mumbai. The median age was 36 years, ranging from 17 to 68 years. The male-to-female ratio at the 2 centers was 1.0:1.03. At the time of patient recruitment, onset of fever ranged from 1 to 15 days, with a median at day 4. The clinical and demographic details are shown in (Tables 1 and 2) .
Of the recruited patients, 572 tested positive by IgM and/ or RT-PCR. RT-PCR was positive in 271 (47.37%) patients, CHIKV IgM test was positive in 194 (33.91%) patients, and 107 (18.70%) patients were both IgM and RT-PCR positive. Higher viral load data emphasize the collection of samples to be at the acute phase of infection. Of these 572 patients, information from 228 patients was included for determination of clinical features (Tables 1 and 2 ). The most frequent clinical features were pain in the hand/wrist (78.94%) and elbow (73.68%), restriction in movement (56.14%), anemia (54.82%), and swelling (47.36%). At the time of assessment, 128 patients (56.14%) reported restricted joint movement related to CHIKV infection (Table 1) . Joint swelling was observed in 108 patients (47.36%); this was mainly observed in the small joints of the hand/wrist followed by the elbow. Analysis of joint restriction revealed that 76.5% of patients in the older age group (aged 46-68 years) exhibited restricted joint movements compared to 23.5% of patients in the younger age group (17-45 years).
Thrombocytopenia was also an important observation, reported in 114 (50%) patients. Follow-up was done for 130 samples after 12 weeks of sample collection and upon physical examination and questioning; VAS was documented in the patients' clinical record forms. Of these 130 samples, 45 (34.6%) patients had a VAS of 0-5 and 85 (65.4%) patients had a VAS of 6-10; the mean VAS was 6.05. Forty samples were taken for further correlation analyses based on the availability of the following data: clinical information, viral load, quantitative IgM, IgG, neutralization status, and VAS. For these 40 patient, onset of fever ranged from 2 to 7 days, with viral load ranging from 1 × 10 +5 to 1 × 10
+9
; a VAS of 6-10 was observed in 25 patients, whereas a VAS of 5-10 was observed in 15 patients (mean VAS, 6.02; Supplementary Table 1) .
Initial Viral Load Correlates With Disease Prognosis
Viral copy number analysis was done for 263 samples, of which 160 (60.83%) patients showed viral loads ranging from 1 × 10 +3 to 1 × 10 +9 on a log-normalized scale (Figure 2a) . Figure 2b ). In patients who were recruited as late as day 12 post onset of fever, we were able to detect viral RNA (1 × 10 +5
). Viral load and days to onset of fever were found to be significant (P < .05).
Forty samples for which complete clinical and follow-up information was available were evaluated to determine the correlation between initial viral load and disease progression with respect to persistent arthralgia. The viral load was plotted against joint movement (restricted vs nonrestricted) at the time of enrollment. The VAS score (1-5 and 6-10) was Figure 2 . Viral load analysis performed on patient samples included in the study at various levels. A, Viral RNA (VNA) load in patient samples (N = 263). Black lines show the medians; white lines represent individual data points; polygons represent the estimated density of the data; samples below thick black line are below detectable range. B, Viral load vs days to onset of fever (N = 160). Day-wise mean viral load is plotted and standard error of mean is represented in the graph. Data for viral load vs days to onset of fever is statistically significant (P < .05). C, Viral load vs disease severity (N = 40), statistically significant (P < .05). Center lines show the medians; box limits indicate the 25th and 75th percentiles as determined using R software; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots; crosses represent sample means; width of the boxes is proportional to the square root of the sample size; data points are plotted as open circles. n = 20, 24, 3, 19 sample points. Abbreviations: VAS, visual analog score; VNA, viral RNA. determined during follow-up after 12 weeks. Twenty-three patients (65%) with higher viral load suffered severe chronic pain as substantiated by higher VAS (VAS > 5) irrespective of joint movement restrictions at the acute phase (Figure 2c ).
CHIKV-Specific Binding Antibodies Correlate With Neutralizing Antibodies
Since we observed that initial viral load dictates increased clinical severity, we then determined whether patients who eventually did not develop chronic symptoms (nonrestricted joints + low VAS) had higher levels of CHIKV-specific binding or neutralizing antibodies. It has been demonstrated in mouse models that passive transfer of anti-CHIKV antibodies can clear viral infection [15, 16] . Earlier studies have demonstrated that not all antibodies made during an active infection are neutralizing and that neutralization ability can mature over time. Therefore, we first asked whether the CHIKV IgG binding antibody titers correlated with neutralizing antibody titers, such that either one of the readouts could be used for further analysis. We analyzed CHIK-specific IgG antibodies and their neutralizing titers in 393 samples. Interestingly, though these patients were either viral RNA positive or IgM positive, more than half of them (57.25%) had CHIKV-specific IgG antibodies at the acute stage of disease (Figure 3) . Importantly, 181 of the 225 IgG-positive patients (80.44%) had neutralizing antibodies to chikungunya, and correlation analysis of binding and neutralizing antibody titers revealed that there was a significant level of correlation between the 2 (R = 0.69, P < .05). In addition, analysis of a subset of these patients at the post-acute phase revealed that at least 10 of the 27 patients whose joint movements were not restricted had significantly higher levels of neutralizing antibodies to CHIKV when compared to none of the patients who eventually had restricted joint movements at post-acute time points, suggesting that early IgG seroconversion may influence the chronicity of infection (Figure 4 ).
Comparative Analysis of Samples From 2 Study Sites
The 2 clinical sites chosen for this study exhibit distinct characteristics with respect to geography, vector transmission, and history of CHIKV circulation, which prompted us to perform a comparative analysis between the 2 study groups. Analysis of viral load between the 2 study populations revealed that Delhi and Mumbai patients showed viral load titer means of 2.37 × 10 +8 and 2.9 × 10 +9 , respectively (Figure 5a) . Furthermore, comparative analysis of CHIKV neutralization antibody titers between the 2 clinical sites revealed that 58.3% (165/283) of patients from Delhi showed detectable PRNT 50 compared to 13.5% (35/260) of patients in Mumbai (Figure 5b ).
DISCUSSION
Our prospective study, conducted between 2010 and 2013, shows clinical and laboratory features of 572 chikungunya patients. To the best of our knowledge, this is the largest study of CHIKV. Figure 3 . Correlation between immunoglobulin G and neutralization status (plaque reduction neutralization test 50) of the patient sera samples included in the study. Spearman correlation between the 2 variables is significant (P < .05), R value is 0.69, and slope is significantly nonzero, P value <.05. Abbreviations: IC, inhibitory concentration; IgG, immunoglobulin G.
Viral load at time of admission was evaluated in 263 patients and in a subset of these patients; viral load was correlated with acute arthralgic and chronic arthritic conditions. After the 2005 CHIK outbreaks in several parts of the world, studies have shown early clinical and laboratory features in patients [17] [18] [19] , disease progression markers [20, 21] , copy number variations [22] , and disorders associated with CHIK post-infection [23] [24] [25] . While our study discusses the above features over a larger patient population, our study was designed to ascertain if any clinical parameters, viral load, or CHIKV neutralizing antibody titers at the time of acute disease could eventually be used to predict disease severity outcomes and the sequelae of persistent joint pain at the post-acute stage of the disease.
A recent study revealed that high viral loads were associated with higher levels of cytokines interleukin-6 and monocyte chemotactic protein (MCP)-1 in chikungunya patient plasma. Of these, MCP-1 was shown to be associated with perpetuation of clinical symptoms in the post-acute phase [26] . Another independent study comprehensively analyzed viral load in patients who recovered after acute illness vs those who did not. It was shown that patients with high viral load during acute illness had higher disposition to continue into a "chronic" phase of the disease [26, 27] . While these studies were done using fewer samples (<30) and correlated viral load to inflammatory cytokines, our study provides direct evidence of the impact of higher viral load on severity during the chronic phase through higher VAS in a much larger patient population. These observations suggest that detection of high initial viral load can be used as a surrogate marker for identifying patients who may have poor prognosis during the post-acute phase of the illness.
A persistent IgM humoral immune response has also been shown to have poor prognosis for disease outcome and severity. However, the role of IgG was not discussed or evaluated in depth. One study showed that passive transfer of convalescent phase sera that contain neutralizing antibodies resulted in sterilizing immunity of CHIKV-infected Ifnr-/-mice, thus indicating a role of anti-CHIKV IgG antibodies in disease outcome [28] . A thorough literature search did not reveal any longitudinal analysis that could provide information on the time course of seroconversion during chikungunya infection in humans. Recent studies of other infections that manifest as only primary infection such as Ebola virus infection have revealed that seroconversion can occur upon initial viral infection and onset of symptoms [29] . Therefore, we hypothesized that there was a possibility that CHIKV patients could develop anti-CHIKV IgG antibodies during the acute phase of the illness and that the presence of IgG antibodies may result in neutralization of CHIKV. Next, we analyzed the levels of both IgG binding and neutralizing antibodies to CHIKV in 225 CHIK-confirmed patients. Surprisingly, a large proportion of them (80.44%) had CHIKV neutralizing antibody titers. Since all patients still had active acute disease at the time of recruitment, we are the first to demonstrate early seroconversion and the presence of anti-CHIKV-specific IgG responses during the acute phase of chikungunya disease. Moreover, in a correlation analysis of the presence of anti-CHIKV neutralization antibodies to VAS in the post-acute phase, we observed that patients who developed anti-CHIKV neutralization antibodies during the acute phase of illness had lower VAS scores during follow-up. These data support our hypothesis that early formation of CHIKV IgG neutralizing antibodies might decrease overall viral load and subsequently result in resolution of disease rather than progression toward persistent joint pain.
When we segregated anti-CHIKV neutralization titers in the patients recruited in Mumbai from those recruited in Delhi, surprisingly, we observed that 58.3% patients from Delhi displayed detectable PRNT 50 as opposed to 13.5% patients in Mumbai. Since CHIKV infection is suggested to confer lifelong immunity, and no epidemiological study has documented any secondary CHIKV infections, one can safely assume that all patients who were recruited with confirmed CHIKV symptoms from either Mumbai or Delhi were previously CHIKV naive or unexposed. Though, currently we cannot determine why there would be such a significant difference in the frequency of patients with CHIKV neutralization from the 2 clinical sites, we suspect that this may be a consequence of the initial dose of virus inoculum during CHIKV infection. Studies performed on hamsters with different doses of Powassan virus have demonstrated that lower-dose inoculum results in higher IgG responses compared to high virus doses [30] . Mumbai has a prolonged wet season and thus may have a higher population of vectors that carry the virus for a longer time period compared to Delhi. This might result in high initial single-dose/cumulative inoculum in Mumbai patients compared to patients from Delhi and thus result in significant differences in anti-CHIKV neutralizing antibody responses, as observed in this study. However, this hypothesis has yet to be tested.
Our study, conducted between 2010 and 2013, is one of the largest to evaluate clinical, laboratory, serological, and viremic aspects of chikungunya infection. Due to a paucity of samples in some years (as few as 1 sample in some years), we could not conduct a year-wise analysis of the changing scenario of the disease. Similarly, our study design did not permit a healthy cohort, and thus we can not comment on preexisting neutralization status in our population. In spite of these caveats, our study sheds light on chikungunya disease with respect to initial viral load and disease progression and provides evidence of high neutralization among patients that may impact disease outcome. There is a need to conduct nation-wide serosurveillance programs in order to clearly identify high-risk populations and initiate disease control programs in that population to reduce disease occurrence in the country.
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